SBIR/STTR Research Award

Rapid manufacturing of recombinant nucleosomes for high-throughput assays

Award identifier 227f7fcbae859cfc646b51ba5ebfc349d0727e13c48d791b7ee210b2bdd05706Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,441

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EPICYPHER, INC.
Proposal award date
2016-07-01
Contract end date
2017-12-31
UEI
UWNWSADJYYZ3
Solicitation number
PA15-269
Topic code
100

Research abstract

DESCRIPTION provided by applicant Chromosomes are composed of genomic DNA and associated protein components that exert powerful regulatory effects The nm nucleosome represents the functional unit of chromatin comprising turns of genomic DNA bp wrapping an octamer of histone proteins Post translational modification PTM of the histones e g methylation acetylation or ubiquitination represents a central epigenetic regulatory mechanism with specific modifications recruiting effector proteins Effector proteins or more often protein complexes can include transcription factors responsible for initiating or blocking the expression of specific genes The andquot histone code hypothesisandquot asserts that certain combinations of histone PTMs on a given nucleosome exert an ensemble impact on downstream gene expression through the recruitment of various effector proteins and complexes Aberrant PTM regulation has been linked to changes in gene expression associated with specific disease states Given the link between PTMs and disease enzymes responsible for the addition and removal of certain PTMs have become the targets of drug discovery efforts with several compounds achieving marketing clearance A broad range of compelling epigenetic drug targets therefore exist including enzymes that add PTMs to histone proteins andapos writersandapos those that bind specific PTMs andapos readersandapos and those that remove PTMs andapos erasersandapos To study these interactions peptides or recombinant histones can be synthetically modified to contain PTMs but these substrates fail to replicate chromatin architecture EpiCypher tm has pioneered the production of PTM modified nucleosomes called designer nucleosomes While these methods are effective synthesis of a single new designer nucleosome can take weeks depending on the number of histone PTMs to add and the quality control steps required to ensure a pure product Condensing this process to or weeks would allow EpiCypher to produce a greater number of modified nucleosomes dramatically expanding the utility of these reagents Current screening of a given writer reader or eraser for PTM context dependent activities requires the use of either hundreds of modified peptides or a priori knowledge of the PTMs of interest to focus on a restricted handful of designer nucleosomes Rapid high throughput manufacturing of PTM carrying nucleosomes will enable EpiCypher to load each well of a well plate with unique nucleosomes enabling a dramatic increase in the throughput of these assays with substrates that more accurately represent in vivo chromatin structure Recent research advancements have developed means to rapidly synthesize proteins carrying specific PTMs using AMBER suppression technology Continuing these research efforts we will develop for the first time methods for commercial scale synthesis of designer nucleosomes carrying mono di or trimethyl PTMs This innovative advancement in designer nucleosome manufacturing will provide a transformational opportunity for drug discovery and the identification of novel therapeutic strategies PUBLIC HEALTH RELEVANCE Post translational modification PTM of histone proteins represents a central epigenetic regulatory mechanism with specific modifications regulating the recruitment of effector proteins to chromatin thereby potentiating or inhibiting downstream gene expression programs To date recombinant nucleosomes are slow to produce and modify limiting their utility in high throughput screening applications Here EpiCypher will optimize a novel means of scaling the production of PTM modified nucleosomes enabling the use of designer nucleosomes in high throughput screens for novel drug discovery and innovative assay development

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

64 SBIR/STTR records share this UEI (2014–2025). Reported award amounts total $79,150,531. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.